

Remarks

Claims 24-26 and 29-38 were pending in the subject application. Claims 24-26 and 29-35 have been allowed. By this Amendment, the applicants have amended claim 36 and cancelled claim 37. No new subject matter has been added by this amendment. Accordingly, claims 24-26, 29-36, and 38 are now pending.

Initially, the applicants would like to thank the examiner for the indication of allowable subject matter.

The amendments set forth herein should not be interpreted to indicate that the applicants have agreed with, or acquiesced to, the rejections set forth in the outstanding Office Action. The amendments to the claims have been made in an effort to lend greater clarity to the claimed subject matter and to expedite prosecution. Favorable consideration of the claims now presented, in view of the remarks and amendment set forth herein, is earnestly solicited.

Claims 36-38 have been rejected under 35 U.S.C. §112, first paragraph as being non-enabled. The applicants respectfully traverse this ground for rejection to the extent that it might be applied to the claims now presented for examination.

In making this rejection the examiner emphasizes the unpredictability and difficulty in treating the various diseases that may be caused by retroviruses. In order to expedite prosecution by addressing the examiner's concerns, the applicants have amended claim 36 by deleting reference to "diseases caused by retroviruses." Instead, claim 36 now focuses on the ability of the claimed compounds to inhibit replication of retroviruses. The ability of these compounds to inhibit retroviral replication is clearly demonstrated in the subject specification including at, for example, pages 18-20. Accordingly, the applicants respectfully request reconsideration and withdrawal of this rejection under 35 U.S.C. §112, first paragraph.

Claims 36-38 have also been rejected under 35 U.S.C. §112, first paragraph, for failing to comply with the "written description" requirement. As noted above, the applicants have amended claim 36 by deleting reference to "diseases caused by retroviruses" thereby rendering moot this rejection under 35 U.S.C. §112, first paragraph.

In view of the foregoing remarks and the amendments above, the applicants believe that the currently pending claims are in condition for allowance, and such action is respectfully requested.

The Commissioner is hereby authorized to charge any fees under 37 CFR §§1.16 or 1.17 as required by this paper to Deposit Account No. 19-0065.

The applicants also invite the Examiner to call the undersigned if clarification is needed on any of this response, or if the Examiner believes a telephone interview would expedite the prosecution of the subject application to completion.

Respectfully submitted,

A handwritten signature in black ink, reading "David Saliwanchik". The signature is written in a cursive, flowing style.

David R. Saliwanchik  
Patent Attorney  
Registration No. 31,794  
Phone: 352-375-8100  
Fax No.: 352-372-5800  
Address: P.O. Box 142950  
Gainesville, FL 32614-2950

DRS/yvs